Is bosutinib suitable for use in pediatric patients?

According to the latest information about Bosutinib released by the U.S. Food and Drug Administration (FDA), it is an oral anti-leukemia drug suitable for adults and children aged 1 year and above with chronic myelogenous leukemia (CML). This decision marks a new breakthrough for bosutinib in the treatment of chronic myelogenous leukemia in children. Bosutinib is a TKI that is part of the treatment for patients with chronic myeloid arthritis, and animal experiments suggest that bosutinib may slow growth to a lesser extent than otherTKIs. Therefore, bosutinib can be used to treat pediatric CML patients, but it needs to be done under the guidance of a doctor and follow the appropriate dosage and course of treatment.